Compare Stocks: PLRX, NVS, CPRX, and NBIX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPRX Catalyst Pharmaceuticals	$31.49	$31.46	$19.05 ▼ $32.56	$3.86B	0.74	2.62 million shs	N/A
NBIX Neurocrine Biosciences	$152.57 -0.2%	$167.14	$122.14 ▼ $186.12	$15.51B	0.39	1.46 million shs	1.23 million shs
NVS Novartis	$159.06 +1.8%	$154.35	$121.57 ▼ $170.46	$303.13B	0.45	1.57 million shs	1.18 million shs
PLRX Pliant Therapeutics	$1.16 +3.1%	$1.11	$1.02 ▼ $1.95	$71.52M	1.24	414,743 shs	504,685 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPRX Catalyst Pharmaceuticals	0.00%	0.00%	0.00%	+0.74%	+54.82%
NBIX Neurocrine Biosciences	0.00%	-0.10%	-12.39%	-2.64%	+14.52%
NVS Novartis	0.00%	+5.32%	+1.75%	+4.55%	+25.07%
PLRX Pliant Therapeutics	0.00%	+7.94%	+6.94%	-4.55%	-19.23%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPRX Catalyst Pharmaceuticals	$31.49	$31.46	$19.05 ▼ $32.56	$3.86B	0.74	2.62 million shs	N/A
NBIX Neurocrine Biosciences	$152.57 -0.2%	$167.14	$122.14 ▼ $186.12	$15.51B	0.39	1.46 million shs	1.23 million shs
NVS Novartis	$159.06 +1.8%	$154.35	$121.57 ▼ $170.46	$303.13B	0.45	1.57 million shs	1.18 million shs
PLRX Pliant Therapeutics	$1.16 +3.1%	$1.11	$1.02 ▼ $1.95	$71.52M	1.24	414,743 shs	504,685 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPRX Catalyst Pharmaceuticals	0.00%	0.00%	0.00%	+0.74%	+54.82%
NBIX Neurocrine Biosciences	0.00%	-0.10%	-12.39%	-2.64%	+14.52%
NVS Novartis	0.00%	+5.32%	+1.75%	+4.55%	+25.07%
PLRX Pliant Therapeutics	0.00%	+7.94%	+6.94%	-4.55%	-19.23%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPRX Catalyst Pharmaceuticals	2.56	Moderate Buy	$32.00	1.62% Upside
NBIX Neurocrine Biosciences	2.88	Moderate Buy	$200.86	31.65% Upside
NVS Novartis	2.31	Hold	$141.20	-11.23% Downside
PLRX Pliant Therapeutics	1.75	Reduce	$3.00	159.74% Upside

Current Analyst Ratings Breakdown

Latest PLRX, NVS, CPRX, and NBIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	NBIX Neurocrine Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$196.00 ➝ $182.00
8/11/2026	NBIX Neurocrine Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/4/2026	NBIX Neurocrine Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/3/2026	NBIX Neurocrine Biosciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$200.00 ➝ $210.00
8/3/2026	NBIX Neurocrine Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$200.00 ➝ $213.00
8/3/2026	NBIX Neurocrine Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$185.00 ➝ $194.00
7/31/2026	NBIX Neurocrine Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$246.00 ➝ $249.00
7/31/2026	NBIX Neurocrine Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$195.00 ➝ $198.00
7/31/2026	NBIX Neurocrine Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$193.00 ➝ $196.00
7/31/2026	NBIX Neurocrine Biosciences	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$200.00 ➝ $220.00
7/24/2026	NVS Novartis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy (B)

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPRX Catalyst Pharmaceuticals	$596.96M	6.46	$2.92 per share	10.77	$7.76 per share	4.06
NBIX Neurocrine Biosciences	$2.86B	5.42	$5.01 per share	30.44	$36.34 per share	4.20
NVS Novartis	$54.53B	5.57	$10.75 per share	14.79	$21.98 per share	7.24
PLRX Pliant Therapeutics	$1.58M	45.26	N/A	N/A	$2.37 per share	0.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPRX Catalyst Pharmaceuticals	$214.33M	$1.74	18.10	10.22	0.96	37.08%	35.76%	31.31%	N/A
NBIX Neurocrine Biosciences	$478.60M	$6.82	22.37	16.13	0.71	20.91%	22.43%	15.64%	10/27/2026 (Estimated)
NVS Novartis	$13.98B	$6.63	23.99	16.21	2.72	23.29%	38.56%	14.47%	10/27/2026 (Estimated)
PLRX Pliant Therapeutics	-$149.34M	-$1.49	N/A	N/A	N/A	N/A	-52.17%	-40.46%	11/5/2026 (Estimated)

Latest PLRX, NVS, CPRX, and NBIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	PLRX Pliant Therapeutics	-$0.3418	-$0.36	-$0.0182	-$0.36	N/A	N/A
7/31/2026	Q2 2026	NBIX Neurocrine Biosciences	$1.65	$2.85	+$1.20	$1.39	$891.16 million	$959.00 million
7/21/2026	Q2 2026	NVS Novartis	$2.17	$2.41	+$0.24	$1.71	$14.07 billion	$14.41 billion
6/30/2026	Q2 2026	NVS Novartis	N/A	$2.41	N/A	$1.71	N/A	$14.95 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPRX Catalyst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A
NVS Novartis	$3.08	1.94%	+5.28%	46.46%	N/A
PLRX Pliant Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPRX Catalyst Pharmaceuticals	N/A	7.10	6.84
NBIX Neurocrine Biosciences	N/A	1.87	1.75
NVS Novartis	0.89	0.86	0.67
PLRX Pliant Therapeutics	N/A	9.90	9.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPRX Catalyst Pharmaceuticals	79.22%
NBIX Neurocrine Biosciences	92.59%
NVS Novartis	13.12%
PLRX Pliant Therapeutics	97.30%

Insider Ownership

Company	Insider Ownership
CPRX Catalyst Pharmaceuticals	10.40%
NBIX Neurocrine Biosciences	4.60%
NVS Novartis	0.01%
PLRX Pliant Therapeutics	8.74%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPRX Catalyst Pharmaceuticals	80	122.42 million	109.69 million	Optionable
NBIX Neurocrine Biosciences	2,000	101.65 million	96.97 million	Optionable
NVS Novartis	75,267	1.91 billion	1.91 billion	Optionable
PLRX Pliant Therapeutics	90	61.92 million	56.51 million	Optionable

PLRX, NVS, CPRX, and NBIX Headlines

Recent News About These Companies

Brokerages Set Pliant Therapeutics, Inc. (NASDAQ:PLRX) Target Price at $3.00

August 23 at 3:31 AM | americanbankingnews.com

Head to Head Review: Zealand Pharma A/S (OTCMKTS:ZLDPF) & Pliant Therapeutics (NASDAQ:PLRX)

August 22 at 3:45 AM | americanbankingnews.com

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

August 18, 2026 | globenewswire.com $https://www.globenewswire.com/news-release/2026/08/18/3346838/0/en/pliant-therapeutics-receives-fda-fast-track-designation-for-pln-101095-in-combination-with-pembrolizumab-for-the-treatment-of-ici-refractory-solid-tumors.html$

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of "Reduce" by Brokerages

August 18, 2026 | marketbeat.com

Monaco Asset Management SAM Purchases Shares of 1,938,747 Pliant Therapeutics, Inc. $PLRX

August 17, 2026 | marketbeat.com

Wall Street Zen Downgrades Pliant Therapeutics (NASDAQ:PLRX) to Sell

August 15, 2026 | americanbankingnews.com

Pliant Therapeutics (NASDAQ:PLRX) Downgraded by Wall Street Zen to Sell

August 15, 2026 | marketbeat.com

Oppenheimer Sticks to Their Hold Rating for Pliant Therapeutics (PLRX)

August 14, 2026 | theglobeandmail.com

Pliant Therapeutics, Inc.: Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 12, 2026 | finanznachrichten.de

Pliant Therapeutics (NASDAQ:PLRX) Posts Earnings Results, Misses Estimates By $0.02 EPS

August 11, 2026 | marketbeat.com

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 11, 2026 | globenewswire.com

Pliant Therapeutics (PLRX) Expected to Release Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

Pliant Therapeutics, Inc. $PLRX Stock Position Raised by ADAR1 Capital Management LLC

July 29, 2026 | marketbeat.com

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Reduce" by Brokerages

July 24, 2026 | marketbeat.com

Pliant Therapeutics adds independent directors to strengthen R&D

July 13, 2026 | tipranks.com

Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D.

July 13, 2026 | globenewswire.com

Pliant Therapeutics Shareholders Approve Directors and Executive Pay

June 11, 2026 | tipranks.com

Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

May 22, 2026 | seekingalpha.com

Pliant Therapeutics Announces Enrollment in Phase 1b Trial of PLN-101095 for ICI-Refractory Solid Tumors at ASCO 2026

May 21, 2026 | quiverquant.comQ

Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 21, 2026 | globenewswire.com

Pliant Therapeutics Stock Short Interest Report | NASDAQ:PLRX | Benzinga

May 17, 2026 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX, NVS, CPRX, and NBIX Company Descriptions

Catalyst Pharmaceuticals NASDAQ:CPRX

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Neurocrine Biosciences NASDAQ:NBIX

$152.57 -0.36 (-0.24%)

As of 08/21/2026 04:00 PM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Novartis NYSE:NVS

$159.06 +2.82 (+1.80%)

As of 08/21/2026 03:58 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Pliant Therapeutics NASDAQ:PLRX

$1.16 +0.04 (+3.13%)

As of 08/21/2026 04:00 PM Eastern

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLRX, NVS, CPRX, and NBIX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLRX, NVS, CPRX, and NBIX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLRX, NVS, CPRX, and NBIX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX, NVS, CPRX, and NBIX Company Descriptions

Catalyst Pharmaceuticals NASDAQ:CPRX

Neurocrine Biosciences NASDAQ:NBIX

Novartis NYSE:NVS

Pliant Therapeutics NASDAQ:PLRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLRX, NVS, CPRX, and NBIX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLRX, NVS, CPRX, and NBIX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLRX, NVS, CPRX, and NBIX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX, NVS, CPRX, and NBIX Company Descriptions

Catalyst Pharmaceuticals NASDAQ:CPRX

Neurocrine Biosciences NASDAQ:NBIX

Novartis NYSE:NVS

Pliant Therapeutics NASDAQ:PLRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools